3201 Carnegie Avenue
United States - Map
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The companys lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
|Dr. Gil Van Bokkelen Ph.D.,
Co-Founder, Chairman and Chief Exec. Officer
|Mr. William Lehmann Jr., J.D., MBA,
Pres, Chief Operating Officer and Sec.
|Dr. John J. Harrington Ph.D.,
Co-Founder, Chief Scientific Officer, Exec. VP and Director
|Ms. Laura K. Campbell CPA,
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
|Dr. Robert J. Deans Ph.D.,
Exec. VP of Regenerative Medicine
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|